NASDAQ$AUPH
Aurinia Pharmaceuticals Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Aurinia reported a 21% increase in total net revenue for Q4 2022, reaching $28.4 million. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.
Aurinia Pharmaceuticals Inc. reported a total net revenue of $28.4 million for the fourth quarter of 2022, representing a 21% increase compared to the same period in 2021. The company's cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.
- Total net revenue for Q4 2022 was $28.4 million, a 21% increase over Q4 2021.
- Net product revenue for Q4 2022 was $28.3 million.
- Aurinia added 406 PSFs during the fourth quarter 2022, a 15% decrease from the fourth quarter 2021 (477).
- Cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022.
Headline financials
Revenue & EPS history
Aurinia · Revenue · Quarterly
$28.4M
Revenue by segment
Aurinia · $28.3M total across 1 segment · Q4 2022
- Net Product Sales$28.3M+21.2%100.0%
Forward guidance
For fiscal year 2023, the Company is reiterating its previous net product revenue guidance of $120 to $140 million from sales of LUPKYNIS. This range represents a double-digit percentage increase in net product revenue from sales of LUPKYNIS compared to fiscal year 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-1.4%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+4.6%
Avg return
30 days after
41%
18 / 44 earnings
Positive
+25.7%
Q2 2021
Best reaction
-32.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.0% | -1.6% | -2.6% | |
| Q4 2025 | -3.1% | -1.9% | -1.1% | |
| Q3 2025 | -3.4% | +8.5% | +8.1% | |
| Q1 2025 | +1.8% | +2.4% | +1.1% | |
| Q4 2024 | -5.0% | +1.6% | +4.3% | |
| Q3 2024 | +10.6% | +11.4% | +18.8% | |
| Q2 2024 | -6.5% | -4.4% | +15.8% | |
| Q1 2024 | -1.9% | -1.5% | +4.2% | |
| Q4 2023 | -26.6% | -29.9% | -35.1% | |
| Q3 2023 | +15.4% | +16.3% | +27.1% | |
| Q2 2023 | -3.1% | -4.1% | -6.6% | |
| Q1 2023 | -1.1% | -4.2% | -18.4% | |
| Q4 2022 | +7.9% | +7.9% | +31.8% | |
| Q3 2022 | -32.3% | -29.3% | -33.0% | |
| Q2 2022 | -1.5% | -4.4% | -15.1% | |
| Q1 2022 | +7.1% | +24.9% | +35.2% | |
| Q4 2021 | -26.0% | -34.9% | -23.7% | |
| Q3 2021 | -0.3% | -2.1% | -41.7% | |
| Q2 2021 | +25.7% | +32.9% | +52.9% | |
| Q1 2021 | -17.3% | -8.5% | +1.7% | |
| Q4 2020 | +1.4% | +0.7% | -12.9% | |
| Q3 2020 | -4.0% | -3.1% | +7.3% | |
| Q2 2020 | -1.3% | -2.4% | -0.8% | |
| Q1 2020 | -2.3% | -3.7% | -11.7% | |
| Q4 2019 | -9.0% | -16.9% | -22.1% | |
| Q3 2019 | -2.4% | +13.6% | +245.4% | |
| Q2 2019 | -7.5% | -7.5% | -6.4% | |
| Q1 2019 | +4.3% | +8.9% | +3.6% | |
| Q4 2018 | +8.9% | +3.2% | +0.6% | |
| Q3 2018 | +1.3% | -6.5% | +9.7% | |
| Q2 2018 | +0.4% | -0.9% | +0.4% | |
| Q1 2018 | +7.3% | +20.3% | +5.7% | |
| Q4 2017 | +6.5% | +0.8% | +1.5% | |
| Q3 2017 | -11.0% | -8.5% | -15.3% | |
| Q2 2017 | +1.7% | +4.4% | +13.3% | |
| Q1 2017 | -4.6% | -6.6% | -22.3% | |
| Q4 2016 | +18.7% | -1.5% | -11.0% | |
| Q3 2016 | +1.2% | -0.8% | +13.3% | |
| Q2 2016 | +4.9% | +17.7% | -41.4% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | -4.8% | — | — | |
| Q2 2015 | -4.0% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | -7.2% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro